SecBot SecBot

RDY drug pipeline

$14.70
−0.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±0.9%
1-day, median of 6 events
IV rank
No data
No current options data
Rated drugs
4
1 mixed · 3 neutral
Phase 3 trials
7
2 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and launched in the US (FDA approval ~August 2026). Now in commercial phase, with Fresenius Kabi handling US commercialization.

rituximab Updated Aug 27

What to watch

The FDA approval is already priced in and was announced approximately 3.5 weeks ago. Watch for initial sales data from Fresenius Kabi's US commercialization and Dr. Reddy's quarterly earnings for any biosimilar revenue disclosures. For a diversified pharma company of RDY's size ($10.3B market cap), this single biosimilar is unlikely to be a major share-price mover. The more relevant catalysts would be broader pipeline updates, resolution of the Form 483 at Bachupally, and overall generics/biosimilars segment performance.

Bull case
  • FDA approval validates Dr. Reddy's capabilities in developing and manufacturing complex biologic medicines for regulated markets, enhancing its credibility.
  • Fresenius Kabi's established US oncology/immunology sales infrastructure should enable meaningful market penetration.
  • Dr. Reddy's already has a commercial presence for rituximab in Europe, India, and emerging markets, providing international revenue streams.
Bear case
  • At least three rituximab biosimilars (Truxima, Ruxience, Riabni) were already approved in the US before Dr. Reddy's entry, creating a crowded market with pricing pressure.
  • Dr. Reddy's does not directly commercialize in the US, Fresenius Kabi handles US sales, so Dr. Reddy's captures only the manufacturing/supply margin rather than full commercial value.
  • Dr. Reddy's is a large, diversified pharma company where this single biosimilar represents a modest revenue contributor, not a material growth driver.
◆ mixed
Impact
PhaseApproved - Generic
Time to marketAlready launched in India (March 2026) and Canada (May 2026), but supply halted until ~October 2026 due to API impurity. US market entry not expected until patent exclusivity ends ~2031-2032.

semaglutide Updated Jul 9

What to watch

Watch for Dr. Reddy's API remediation progress and the late-October 2026 supply restart timeline. The supply halt halved the FY27 production target from 12M to 6-7M pens and erased ~$678M in market cap. Any update on resolving the impurity issue, regulatory findings, or competitive dynamics (Apotex, USV) could move shares. US market entry (2031-2032 patent expiry) is the long-term prize but too distant to trade on now.

Bull case
  • Semaglutide is one of the largest pharmaceutical markets in history, Novo Nordisk's Ozempic/Wegovy generated tens of billions in revenue. Generic entry captures a fraction of that at much lower prices, with massive volume potential.
  • Dr. Reddy's was the first company to receive Health Canada approval for a generic semaglutide injection (April 28, 2026), a first-mover advantage in the G7. The company launched commercially on May 15, 2026 across Canadian pharmacies including Shoppers Drug Mart and Rexall.
  • The company set a ~$100M revenue target from semaglutide in Canada alone for FY27. Even halved to 6-7M pens, this represents meaningful incremental revenue against total FY2026 revenue of $3.63B.
Bear case
  • Dr. Reddy's halted semaglutide production on July 9, 2026 after detecting an unknown impurity in its own API, with supply disruptions expected until at least late October 2026. The stock fell ~6.5% and $678M in market cap was erased. The FY27 production target was cut from 12M to 6-7M pens.
  • US market, the biggest prize, remains locked until 2031-2032 by Novo Nordisk's composition-of-matter patents. Apotex already received tentative FDA approval for generic semaglutide (April 2026) and is positioned for US launch upon patent expiry.
  • Competition in India is intensifying rapidly, USV launched its own generic (Usema), and multiple Indian drugmakers are entering the GLP-1 space after the April 2026 patent cliff in India.
● neutral
Impact
PhaseApproved
Time to marketAlready approved by CDSCO (India) in July 2026; anticipated to become available in India's private market in the first half of 2027.

QDENGA dengue tetravalent vaccine (live attenuated) Updated Oct 24

What to watch

Watch for the commercial launch of QDENGA in India's private market in H1 2027, which will be Dr. Reddy's first foray into vaccine distribution. The financial terms were not disclosed, so the revenue contribution is unclear, this is a distribution deal, not a development deal, and is unlikely to be a needle-mover for a ~$11B market cap company. Monitor quarterly results for any disclosed revenue from the partnership.

Bull case
  • QDENGA is an approved, commercially established vaccine in multiple global markets (EU, UK, Brazil, Argentina, Indonesia, Thailand), Dr. Reddy's is not taking development risk.
  • India has a high dengue burden, creating a large addressable market for the vaccine in the private sector.
  • Dr. Reddy's strong India commercial infrastructure (17% YoY growth in India segment in Q2FY27) provides a ready distribution channel.
Bear case
  • Dr. Reddy's is only a distributor, not the developer, margins on distribution deals are typically thin and the financial terms were not disclosed, suggesting limited materiality.
  • India's private vaccine market is price-sensitive; dengue vaccination is not part of the national immunization program, limiting volume potential.
  • QDENGA faces potential competition from other dengue vaccines (e.g., Sanofi's Dengvaxia) and any future entrants.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market — generic sugammadex is commercially available from Dr. Reddy's and multiple other manufacturers.

sugammadex Updated Oct 24

What to watch

Sugammadex is a mature generic product within Dr. Reddy's broad portfolio, not a standalone catalyst. Investors should watch Dr. Reddy's Q3 FY2027 earnings (due January 2027) for North America generics revenue trends and any updates on semaglutide-related charges, which are far more material to the stock than sugammadex specifically.

Bull case
  • Sugammadex (Bridion) is a well-established anesthesia reversal agent with steady hospital demand, generic versions benefit from the established market without needing new clinical trials.
  • Dr. Reddy's is a top-tier Indian generic manufacturer with a strong US FDA track record; its scale and distribution network support reliable generic sugammadex sales.
  • Citigroup upgraded RDY from Sell to Buy in September 2026, and the analyst consensus price target mean of ~$13.79 implies ~4.4% upside from the current ~$13.21.
Bear case
  • Sugammadex is a mature generic with multiple competitors, pricing erosion is the norm, not the exception, and Dr. Reddy's does not disclose product-level margins for generics.
  • Dr. Reddy's Q2 FY2027 earnings showed North America generics revenue declining 23% YoY, driven by lenalidomide erosion; sugammadex is a small part of a challenged base business.
  • The stock has a neutral bull/bear signal from SecBot's evidence checklist, with elevated short volume (~44% weighted ratio over 61 sessions) and multiple institutional trims in Q3 2026.

Other drugs in filings and trials

no drug report yet
  • BENDAMUSTINE HYDROCHLORIDE Last: Approval · Jul 3, 2025
  • PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Last: Approval · May 30, 2025
  • REZIPRES Last: Approval · Jun 14, 2021
  • CYCLOPHOSPHAMIDE Last: Approval · Jul 30, 2020
  • BIORPHEN Last: Approval · Oct 21, 2019
  • BORTEZOMIB Last: Approval · Oct 4, 2019
  • Azacitidine and Venetoclax 1 trial
  • Estradiol 1 trial
  • Imatinib 1 trial
  • Pramipexole 2 trials
  • Rivaroxaban 15 MG Oral Tablet [Xarelto] 1 trial
  • S65487 and azacitidine 1 trial
  • Tolcapone 1 trial
  • Triamcinolone Acetonide 1 trial
  • Valganciclovir 1 trial

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Jul 3, 2025BENDAMUSTINE HYDROCHLORIDEApproval+1.3%−2.5%
May 30, 2025PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDEApproval−0.1%+5.4%
Jun 14, 2021REZIPRESApproval−0.5%−3.2%
Jul 30, 2020CYCLOPHOSPHAMIDEApproval+3.7%+4.4%
Oct 21, 2019BIORPHENApproval+0.2%+0.6%
Oct 4, 2019BORTEZOMIBApproval−1.6%−1.2%

Clinical trials

24 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
IvaltinostatA Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic AdenocarcinomaPhase 2Active not recruiting70Jun 2026
rituximabLow-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaPhase 2Terminated53May 5, 2026
ValganciclovirANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSIONPhase 2Completed20Apr 1, 2026
S65487 and azacitidinePhase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid LeukemiaPhase 2Completed57Mar 27, 2026
Abiraterone AcetateApalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate CancerPhase 2Terminated7Mar 12, 2026
TolcaponeCOMT Inhibition Among Individuals With Comorbid AUD/ADHDPhase 2Completed23Mar 9, 2026
AzacitidineRuxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmPhase 2Completed121Jan 20, 2026
PramipexoleLong-term Efficacy of Pramipexole in Anhedonic DepressionPhase 3Completed55Dec 5, 2025
rituximabInotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell TransplantationPhase 2Terminated · results15Oct 13, 2025
EstradiolEstradiol Therapy In Transgender Women to Research Interactions With HIV TherapyPhase 2Terminated · results93Aug 21, 2025
Rivaroxaban 15 MG Oral Tablet [Xarelto]Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery OcclusionPhase 3Terminated930Jun 26, 2025
PramipexolePramipexole for Anhedonic DepressionPhase 3Completed85Jun 4, 2025
CyclophosphamideSelective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDPhase 2Completed · results84Apr 1, 2025
AzacitidineMagrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaPhase 2Terminated · results110Mar 25, 2025
Azacitidine and VenetoclaxAzacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AMLPhase 2Completed · results42Jan 29, 2025
Triamcinolone AcetonideSymptom Clusters in Children With Exacerbation-prone AsthmaPhase 2Completed · results68Jan 16, 2025
AzacitidineClinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldPhase 2Completed113Nov 30, 2024
ImatinibTrial of Imatinib for Hospitalized Adults With COVID-19Phase 3Terminated · results21Jun 30, 2024
—IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II StudyPhase 2Completed31Aug 31, 2023
CapecitabineMetronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast CancerPhase 3Completed263Aug 25, 2023
Trastuzumab deruxtecanDS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]Phase 3Completed · results608Jun 30, 2022
rituximabAcalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaPhase 2Completed · results13Feb 9, 2020
DUALNew Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis CPhase 2Completed · results—Not stated
SirolimusSirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyPhase 3Terminated—Not stated